ACoP6 Posters


Poster ID Corresponding Author/ Presenter Abstract Title
M-001 Yuan Xiong PMXstan: An R Library to Facilitate PKPD Modeling with Stan (abstract)
M-002 David Tenero Tafenoquine (TQ; SB252263) Population Pharmacokinetic (PK) Model and Efficacious Dose Simulation in Plasmodium vivax Malaria Subjects (abstract)
M-003 L. Li Systematic Comparison of Approaches to Handle Below Quantification Limit Data in Population Pharmacokinetic Analyses (abstract)
M-004 Aniruddha Amrite Sequential Population PK-Viral Dynamic Modeling of  TD-6450, a Next Generation Once Daily NS5A Inhibitor, following 3-Day Monotherapy in Patients with GT-1 HCV Infection (abstract)
M-005 Gilbert Koch Fabry Disease Progression with and without Enzyme Replacement Therapy (abstract)
M-006 Elliot Offman Population Physiologically-Based Pharmacokinetic Model Incorporating Lymphatic Uptake for a Subcutaneously Administered Pegylated Peptide (abstract)
M-007 Meihua R. Feng Population Pharmacokinetics of Mycophenolic Acid and its Glucuronide Metabolite in Lung Transplant Recipients with and without Cystic Fibrosis (abstract)
M-008 Jean Lavigne Modeling and Simulation of Piperaquine (PQ) After Administration of Eurartesim® (PQ Tetraphosphate/Dihydroartemisinin) (abstract)
M-009 Dan Lu Time-to-event analysis of polatuzumab vedotin induced peripheral neuropathy to assist comparison of dosing regimen (abstract)
M-010 Lisa O’Brien Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients (abstract)
M-011 Tomoko Freshwater Assessment of Pembrolizumab (MK-3475) Dosing Strategy Based on Population Pharmacokinetics and Exposure-Response Models  (abstract)
M-012 Ying Hong Model-Based Approach for Dose Optimization of HSP90 Inhibitor Luminespib (abstract)
M-013 Julie Pasarell Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults (abstract)
M-014 Vijay Ivaturi CLIP: The Command-Line Interface to Phoenix NLME (abstract)
M-015 A. Corey Prediction of Anthrax Toxin Protective Antigen Kinetics in Humans (abstract)
M-016 Ho-Pi Lin Combination of R “Shiny” and Application Programming Interface (API) to Create a Browser Based Visualization Tool for FDA Public Database (abstract)
M-018 Michael J. Reed A Quantitative Systems Pharmacology Platform to Investigate the Impact of Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics: Insights for the Clinical Application of PCSK9 Inhibitors  (abstract)
M-019 Roberto Gomeni Modeling Complex PK Profiles of Long Acting Injectable Products Using a Convolution-Based Approach  (abstract)
M-020 Ophelia Yin Longitudinal Exposure-Response Relationship for Mirogabalin in Patients with Diabetic Peripheral Neuropathic Pain  (abstract)
M-021 Phyllis Chan Nonlinear Mixed Effects Modeling of Disease Progression of Placebo Subjects from the Irbesartan Diabetic Nephropathy Trial (abstract)
M-022 Yasong Lu Model-Based Meta-Analyses (MBMA) of DAS28 Reduction in Support of Rheumatoid Arthritis Development Programs (abstract)
M-023 Qi Wang Development of a Physiologically Based Pharmacokinetic Model for Daclastavir and Prediction of Drug-Drug Interactions with P-gp and CYP3A4 Inhibitors (abstract)
M-024 David Z. D’Argenio Feedback Control Indirect Response Models (abstract)
M-025 Kyunghee Yang Mechanistic Modeling with DILIsym® Predicts Dose-Dependent Clincial Hepatotoxicity of AMG 009 That Involves Bile Acid (BA) Transporter Inhibition (abstract)
M-026 Linzhong Li Evaluating the Efficiency of Payload Delivery by ADCs Using a Minimal PBPK Model (abstract)
M-027 Brian J. Schmidt Development of a Quantitative Systems Pharmacology (QSP) Platform to Support Translational Research and Clinical Development in Immuno-Oncology (abstract)
M-028 Emilie Schindler Analyzing Patient-Reported Outcomes in Breast Cancer through Item-Response Theory Pharmacometric Modeling (abstract)
M-029 Denison J. Kuruvilla A Method to Evaluate Fetal Erythropoiesis from Postnatal Survival of Fetal RBCs (abstract)
M-030 Stephen Duffull An Approximation to the Solution of Systems of Nonlinear Ordinary Differential Equations in Pharmacokinetics-Pharmacodynamics (abstract)
M-031 Eric G. Burroughs Immuno-Viral Dynamics Modeling of Letermovir for Treatment of Human Cytomegalovirus (HCMV) Infection in Post-Transplant Settings (abstract)
M-032 Owen JS Pharmacogenetic-Based Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Efavirenz on Adult Ethiopian HIV and TB/HIV Patients (abstract)
M-033 Hugo Geerts From Big Data to Smart Data. How Quantitative Systems Pharmacology Can Support CNS Pharmaceutical R&D (abstract)
M-034 D. Zhang Implementation of Non-linear Mixed Effect Modeling Approach in Allometric Scaling For Human Clearance Prediction (abstract)
M-035 Xiao Hu Prediction of Pharmacokinetic Profiles of an Anti-TWEAK Monoclonal Antibody, BIIB023, in Pediatric patients with Lupus Nephritis  (abstract)
M-036 Hyewon Kim Exploration of Model-Based Bioequivalence (BE) Evaluation as an Alternative Approach for the Sparse Pharmacokinetic (PK) Sampling Design 
M-037 Sebastian Ueckert Evaluation of the Expected Fisher Information Matrix without Linearization, in Nonlinear Mixed Effect Models for Discrete and Continuous Outcomes  (abstract)
M-038 Shuhua Hu Implementation of a highly nonlinear, multi-scaled and long-term HIV dynamic model with treatment interruptions and non-static BQL data for population analysis (abstract)
M-039 Heather E. Vezina Ipilimumab Exposure-Response (E-R) Analysis of Overall Survival (OS) in Patients with Advanced Melanoma (abstract)
M-040 Yanhui Lu Translational Modeling of Regular Human Insulin Pharmacokinetics and Glucose Dynamics in Minipigs (abstract)
M-041 In-Jin Jang Population Pharmacokinetic Analysis of Once Daily Formulation of Tacrolimus in Kidney Transplantation Patients (abstract)
M-042 Steven W. Martin Mechanistic Population Pharmacokinetics Model of PF-00547659, a Full Human lgG2 anti-MAdCAM Monoclonal Antibody in Ulcerative Colitis Patients (abstract)
M-043 Nagdeep Giri Population Pharmacokinetic Model (PopPK) for Dacomitinib and its Metabolite in Healthy Volunteers (HV) and Patients with Advanced Solid Tumors (abstract)
M-044 Kenta Kadotsuji Quantitative Approach to Predicting Human Pharmacokinetics of Monoclonal Antibody (DSP-mAbX) from Preclinical Data (abstract)
M-045 Anasuya Hazra Quantitative Assessment of the Exposure- Response Relationships of PF00547659, a Full Human IgG2 anti-MAdCAM Monoclonal Antibody, as Induction Therapy for Ulcerative Colitis in a Phase 2 Study (abstract)
M-046 Mahesh N. Samtani 8-Year Disease Progression in Asymptomatic at Risk for Alzheimer Dementia (ARAD) Subjects from ADNI-1 (abstract)
M-047 Renu Singh Pharmacokinetic/pharmacodynamic (PK/PD) Characteristics of Veliparib with and without Temozolomide in Patients with Hematological Malignancies (abstract)
M-048 Woodhead JL Quantitative Systems Modeling Provides Biological Plausibility for Potential Mechanisms of Tolvaptan-Induced Hepatotoxicity  (abstract)
M-049 April M. Barbour Application of Complementary Statistical and Modeling Analyses to Identify Predictors of Sustained Virologic Response in Patients with Chronic Hepatitis C  (abstract)
M-050 M. Craig The Robust Response of a Physiological Model of Granulopoiesis to PK Variability (abstract)
M-051 Karen Schneck Mechanistic Model based Assessment of PK/PD Critical Success Factors (CSF) for Next-Generation Ultra-fast Acting Insulins  (abstract)
M-052 Malidi Ahamadi Pooled Population Pharmacokinetic and Immunogenicity Analysis of Pembrolizumab Using Data from KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006 (abstract)
M-053 Ben G Small Repolarisation Rate: An Integrative Biomarker of cCardiac Action Potential Repolarisation (abstract)
M-054 Dong-Seok Yim Overestimation of Shape Parameter of Weibull Base Hazard in the Modeling of Time-To-Event Data (abstract)
M-055 Olivier Barrière inVentR: The Pharmacometrician’s Best Friend (abstract)
M-056 Mélanie Wilbaux Semi-Mechanistic Model to Predict In-Hospital Natural Weight Changes in Term Neonates (abstract)
M-057 Satyendra Suryawanshi Leveraging Longitudinal Tumor Data for Prediction of Overall Survival from I-O therapy: A Proof of Concept with Quantitative Models and External Validation (abstract)
M-058 Gaurav Bajaj Characterization of the Pharmacokinetics and Exposure-Response Relationship for Nivolumab in Patients with Previously Treated or Untreated Advanced Melanoma (abstract)
M-059 Renu Singh  Comparison of Different Methods for Predicting Pharmacokinetics of Monoclonal Antibodies in Human (abstract)
M-060 Timothy J Carrothers PKPD Modeling of Vilazodone (VLZ) in Adult Patients with Generalized Anxiety Disorder (GAD) (abstract)
M-061 Xiaoning Wang Characterizing Exposure-Response (E-R) Relationship of Safety for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma (abstract)
M-062 Kimberley Jackson A PKPD Model Describing the Effect of Ixekizumab on Absolute Psoriasis Area and Severity Index (PASI) score in Patients with Moderate to Severe Plaque Psoriasis  (abstract)
M-063 Craig J. Thalhauser Mechanistic Predictions of Response to Combinations of Biologic Agents in a Quantitative Systems Pharmacology Model of Rheumatoid Arthritis (abstract)
M-064 Christina M. Friedrich Model Qualification Approaches for Quantitative Systems Pharmacology and Mechanistic Physiological Models abstract
M-065 J.S. Macwan Physiologically Based Pharmacokinetic Modeling of Rosuvastatin and Prediction of Transporter-Mediated Drug-Drug Interactions Involving Gemfibrozil (abstract)
M-066 John Harrold A General Method for Initialization of Steady-States in Complex PK/PD Systems (abstract)
M-067 Sihem Ait-Oudhia  In Vivo Mechanisms of Drug-load Release for Antibody Drug Conjugates and Their Relationships To Drug-Related Toxicity (abstract)
M-068 C. Passey Model-Based Analysis to Support Clinical Pharmacology Profiling of Elotuzumab in Patients with Multiple Myeloma (abstract)
M-069 France Mentré Bayesian Fisher Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters with Data Below the Quantification Limit (abstract)
M-070 France Mentré Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Models  (abstract)
T-001 Xiaohua Gong A Compartmental Epidemic and Outcome Model Framework with User-Friendly Interactive Inputs and Dynamic Outputs (abstract)
T-002 Yuan Xiong Non-Homogeneous Poisson Process (NHPP) Analysis of Time to First Flare for Canakinumab (CAN) Dose Justification in SJIA (abstract)
T-003 Harish Shankaran A Mechanism-Based Translational Mathematical Model for Gastrointestinal Toxicity (abstract)
T-004 Scott Van Wart Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Tolvaptan and Diuretic Use on Fluid and Electrolyte Balance in Healthy Subjects (abstract)
T-005 Karen Schneck Enhancing Clinical Utility of Model-based Pharmacokinetic Profiles of Subcutaneous Insulin Through Interactive Visualization (abstract)
T-006 Seung-Wook Chung Systems Pharmacology Modeling and Analysis of Therapeutic Antibodies Antagonizing IL13-Mediated Disease Signaling (abstract)
T-007 Johannes Schropp Uncompetitive and Competitive Drug-Drug Interaction with Target-Mediated Drug Disposition (abstract)
T-008 Daniel Gonzalez Population Pharmacokinetics of Morphine in Patients with Non-Alcoholic Steatohepatitis (NASH) and Healthy Adults (abstract)
T-009 Xiaosu Ma1 Simulation-Based Assessment of Insulin Lispro Dose Titration Algorithms Using a Model of Glucose-Insulin-Glucagon Dynamics (abstract)
T-010 Alanna McEneny-King Web Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo): A Service for Bayesian Post Hoc Estimation (abstract)
T-011 Murad Melhem Quantitative Characterization of the Effects of Acute Radiation (AR) and Treatment with Filgrastim (Neupogen) on Absolute Neutrophil Counts (ANC) and Overall Survival (OS) in Non-Human Primates (NHP)  (abstract)
T-012 Craig Fancourt Development of a Joint PKPD Model of the Hyperinsulinemic Glucose Clamp (abstract)
T-013 Harvey, Jay Relationship Between Eslicarbazepine  Exposure and Efficacy of Eslicarbazepine Acetate Adjunctive Therapy (abstract)
T-014 Alexander C. Ross A Method for Simulating Dopamine Agonist Self-Administration with a Receptor-Based Mechanism (abstract)
T-015 Joel M. Reid Population Pharmacokinetic Model for Oral Endoxifen in Patients with Breast or Gynecologic Cancers (abstract)
T-016 A. Corey Simulated Implications of Predicted PA Kinetics in Humans for Treatment of Inhalational Anthrax (abstract)
T-017 Sameer Doshi Effect of Clinical Study Design on Estimation of Pharmacokinetic Parameters in Pediatric Populations Using Pharmacokinetic Parameters from Adult Populations as Bayesian Priors: Application to Target Mediated Drug Disposition Models (TMDD) (abstract)
T-018 Lora Hamuro Prediction of Human Immunogenicity for a Biotherapeutic Candidate Using a Mechanistic Model of the Immune System (abstract)
T-019 Feng Jin Exposure-Response of Idelalisib, a Novel PI3Kδ Inhibitor, in the Combination Therapy of Chronic Lymphocytic Leukemia  (abstract)
T-020 Liviawati S Wu The Impact of Ribavirin Plasma and Cellular Pharmacokinetics and Host Genetics on Anemia and Antiviral Response to Hepatitis C Treatment  (abstract)
T-021 In-Jin Jang Population Pharmacokinetics of Tarolimus in Pediatric Renal Transplant Recipients on Two Different Formulations - Twice-daily Prograf® and Once-daily Advagraf® (abstract)
T-022 Mirjam N. Trame tVPC: A User-Friendly Matlab-based Tool for the Evaluation and Simulation of Systems Pharmacology Models (abstract)
T-023 Nan Zheng Assessment of Partial AUC Requirement for Bioequivalence Evaluation of Methylphenidate Hydrochloride Extended-Release Oral Suspension (abstract)
T-024 Benjamin Guiastrennec Quantitative Model Diagrams (QMD): A New Perspective in Model Evaluation (abstract)
T-025 Weirong Wang Aqueous Humor VEGF Suppression and Clinical Efficacy of VEGF-targeting Biologics in Age-related Macular Degeneration (abstract)
T-026 Malek F. Okour Comparative Evaluation of Bias And Precision in Compartmental Models of Enterohepatic Circulation  (abstract)
T-027 Dooyeon Jang Interpretation of Drug-Drug Interaction Study Results of Long Elimination Half-Life Drugs: Comparison of Conventional Bioequivalence Test Anda Model-Based Approach (abstract)
T-028 Mélanie Wilbaux Semi-Mechanistic Model to Characterize Effects of Gastric Emptying on Glucose Absorption in Obese and Non-Obese Adults (abstract)
T-029 Geraldine Celliere Towards Improving In Vitro–In Vivo Toxicity Extrapolation Using Multi-Scale Modeling: A Proof of Concept on Paracetamol Hepatotoxicity  (abstract)
T-031 Gilbert Koch1 Delay Differential Equation Solver in ADAPT 5 (abstract)
T-032 Julie Autmizguine Dose-Exposure Simulation for Optimal Piperacillin-Tazobactam Strategy in Infants and Young Children (abstract)
T-033 Sebastian Ueckert Improved Confidence Intervals and P-Values by Sampling from the Normalized Likelihood  (abstract)
T-034 Elodie L. Plan Handling Underlying Discrete Variables with Mixed Hidden Markov Models in NONMEM (abstract)
T-035 Helen Moore Mathematical Optimization of Combination Therapy for Chronic Myeloid Leukemia (CML) (abstract)
T-036 Koichiro Yoneyama Impact of Age on Population Parameter Estimates and Pediatric Prediction Performances of Monoclonal Antibody Clearance: A Simulation Study (abstract)
T-037 Kyung-Sang Yu Population Pharmacokinetics of Voriconazole in Healthy Korean Male with Various CYP2C19 Genotypes  (abstract)
T-038 Manisha Lamba How Quantitative Modeling of a Biomarker was Leveraged in Understanding Pharmacodynamic Recovery: An Illustration using Changes in Natural Killer Cells with Tofacitinib 
T-039 Shuhua Hu A Distributed Delay Approach for Modeling Delayed Outcomes in Pharmacokinetics and Pharmacodynamics Studies (abstract)
T-040 Eric A. Sherer Real-Time Pharmacokinetic Analysis (abstract)
T-041 Markos Leggas Evaluating the Performance of Different Expectation Maximization Algorithms in Handling Complex Pharmacometric Models
T-042 Dana Nickens Exposure-Response Analsysis of Efficacy and Safety Endpoints for Crizotinib in the Treatment of Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (abstract)
T-043 Zheng Jiao The Effect of Poor Compliance on the Pharmacokinetics of Valproic Acid in Children with Epilepsy Using Monte Carlo Simulation (abstract)
T-044 Iñaki F. Trocóniz Towards Patient Stratification in Systemic Lupus Erythematosus using a Systems Pharmacology Approach (abstract)
T-045 Rukmini Kumar Estimating Parameters by Optimization Algorithms in a Simple PK Model with Bifurcations  (abstract)
T-046 Maciej J Swat Pharmacometric Markup Language (PharmML) & Standardised Output (SO) - Encoding Standards for Exchange of Models and Results in Pharmacometrics and Quantitative Systems Pharmacology (abstract)
T-047 Jakob Ribbing Predicting Reductions in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations from FEV1 – A Model-Based Meta-Analysis of Literature Data from Controlled Randomized Clinical Trials (abstract)
T-048 Timothy Bergsma Implementing FDA Specifications in R for Submission of Analysis Datasets (abstract)
T-049 Bojan Lalovic PK-PD Analysis of PASI with Data at Boundary: BI 655066 an Anti-IL-23A mAb for the Treatment of Psoriasis (abstract)
T-050 Rik Schoemaker Modeling the Effect of Levetiracetam on Daily and Aggregated Seizure Counts in Adults and Children
T-051 William S. Denney Simple, Automatic Noncompartmental Analysis: The PKNCA R Package (abstract)
T-052 Daniela J Conrado Facilitating Exposure-Response Analysis of Cardiovascular Safety Markers in Early-Phase Clinical Studies with the cardioModel Package for R (abstract)
T-053 Malidi Ahamadi Model-Based Pooled Analysis of Exposure and Safety of Pembrolizumab with Advanced Melanoma and Non-Small Cell Lung Carcinoma (NSCLC) (abstract)
T-054 Jürgen B. Bulitta Enterohepatic Recirculation and Gender Differences of Roxithromycin in Humans Assessed via Population Pharmacokinetics (abstract)
T-055 Brian J. Schmidt Development of a Quantitative Systems Pharmacology (QSP) Platform to Support Translational Research and Clinical Development of Affinity Drug Conjugates (ADCs) (abstract)
T-056 Yan Feng Exposure-Response (E-R) Analysis of Progression Free Survival (PFS) for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma (abstract)
T-057 Karim Azer Enhancing the Utility of Systems Pharmacology Modeling in Pharmaceutical R&D: Lessons from the development of a PCSK9 Inhibitor Model (abstract)
T-058 Vijay Ivaturi Population Pharmacokinetics of Sorafenib in Acute Myelogenous/B-Type Leukemia Patients (abstract)
T-059 Devin Pastoor Extending Rstudio's Functionality to Accelerate Modeler Workflows via Shiny Applications (abstract)
T-060 Sharon Karan Population PK/PD from a Phase I Study of the Single-Agent PARP Inhibitor, Veliparib, in Patients with PARP Sensitive Tumor Types or BRCA 1/2 –Mutated Cancer (abstract)
T-061 Timothy J Carrothers Population Pharmacokinetic (PPK) Modeling of Vilazodone in Adolescent Patients with Major Depressive Disorder (MDD) (abstract)
T-062 Mohamad-Samer Mouksassi GGplot-Shiny: A Shiny App That Facilitates Data Manipulation And Exploration (abstract)
T-063 Jinzhong Liu SASR (Survival Analysis using “Shiny” R): A Browser Based Survival Analysis Visualization Tool using R “Shiny” (abstract)
T-064 Emmanuel Chigutsa The Effect of Body Weight on Necitumumab Pharmacokinetics and Pharmacodynamics in Patients with Squamous Non-Small Cell Lung Cancer: Dosing Implications (abstract)
T-065 C. Passey Latent Variable Approach to Assess the Time-Varying Effect of Immunogenicity on the Pharmacokinetics of Elotuzumab in Patients with Multiple Myeloma (abstract)
T-066 Chih-Wei Lin Population Pharmacokinetics of ABT-493 in HCV Genotype 1 Infected Subjects with or without Cirrhosis in Three-Day Monotherapy Study (abstract)
T-067 Janelle Hajjar Trends in the Application of Pharmacometric Modeling and Simulation in the Development of Orphan Drugs in the 21st Century (abstract)
T-068 D. Zhang Letermovir Exposure is Similar in HSCT Patients and Healthy Volunteers  (abstract)
T-069 Chay Ngee Lim Phxnlme: An R Package that Faciliates Pharmacometrics Workflow of Phoenix NLME Analyses (abstract)
T-070 Eun Kyoung Chung Comparative Population Pharmacokinetics of Ofloxacin, Ciprofloxacin, Levofloxacin, and Moxifloxacin using Bioequivalence Study Data (abstract)
W-001 Da Zhang Model Based Meta Analysis to Characterize the Dose-Efficacy Profile of Recombinant FSH for Controlled Ovarian Stimulation (abstract)
W-002 Dhananjay Marathe Utilizing Modeling and Simulation to Inform Dose Selection, Titration Algorithms, and Trial Design of Oral Testosterone (T) Products for Testosterone Replacement therapy (TRT) in Hypogonadal Men (abstract)
W-003 Emmanuel Chigutsa Population Pharmacokinetics and Pharmacodynamics of an Oral Glucagon Receptor Antagonist (LY2409021) in Patients with Type 2 Diabetes Mellitus (abstract)
W-004 Kristin Dickschen PBPK Modeling to Guide Experimental Design in Drug Development (abstract)
W-005 Jun Li Model Based and Model Independent Evaluations of Steady-State Volume of Distribution (Vdss) of Two-Compartment Pharmacokinetic Models with Parallel First-Order and Michaelis-Menten Eliminations (abstract)
W-006 Scott Van Wart Pharmacokinetic-Pharmacodynamic (PK-PD) Model for Tolvaptan in Patients with Hypervolemic Hyponatremia   (abstract)
W-007 Manish R. Sharma A Disease Progression Model of Castrate Resistant Prostate Cancer (CRPC) Using Prostate Specific Antigen (PSA)  (abstract)
W-008 Donald E. Mager Pharmacodynamic Model of Vorinostat Effects in Multiple Myeloma Cells and Xenografts (abstract)
W-009 Leonid Gibiansky Target-Mediated Drug Disposition (TMDD) Equations and Approximations for Systems with 1:2 and 2:1 Drug-Target Binding Stoichiometry (abstract)
W-010 Jasper Stevens Population Pharmacokinetic/Pharmacodynamic Modeling of a Next Generation  Recombinant Human Factor VIIa (LR769) to Derive the Dose to be Studied in Phase 3 (abstract)
W-011 Ocampo-Pelland AS Model-Based Meta-Analysis to Develop a Vitamin D Parent-Metabolite Population-Pharmacokinetic Model  (abstract)
W-012 Shringi Sharma Population Pharmacokinetics and Exposure-Response Analysis of Entospletinib, a Selective Spleen Tyrosine Kinase Inhibitor (abstract)
W-013 Eric G. Burroughs A Model-Based Meta-Analysis of Insulin PK-PD in Glucose Clamp Studies of Diabetes Mellitus Type 1 and Non-Diabetic Human Subjects (abstract) 
W-014 Gary Milavetz Population Pharmacokinetics of Ethanol in Moderate and Heavy Drinkers (abstract)
W-015 Leijun Hu Population Pharmacokinetics and Pharmacodynamics of Blosozumab (abstract)
W-016 Murad Melhem  Population Pharmacokinetics and Pharmacodynamics (PK/PD) of AMG 416 in Chronic Kidney Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (sHPT) Receiving Hemodialysis (abstract)
W-017 Andrijana Radivojevic  Datasets for Pharmacometric Analyses: Internal Review and Standardization Efforts (abstract)
W-018 Vijay Ivaturi Pharmacokinetics of Flavopiridol Using Bolus or Hybrid Administration Schedules in the Treatment of Acute Leukemias (abstract)
W-019 Colin Phipps A PBPK Model Platform for Nanoparticles Including Lymphatic and Size-Dependent Transport (abstract)
W-020 Ludwig EA Eslicarbazepine Acetate Drug-Drug Interactions: Characterization Through a Model-Based Population Approach (abstract)
W-021 Ignacio Gonzalez-Garcia Building an Inflammatory Bowel Disease Network, a Systems Pharmacology Approach (abstract)
W-022 Fahima Nekka Identification and Quantification of Noncompliance Patterns Associated to Specific Clinical Outcomes (abstract)
W-023 Kyle T. Baron  Simulation from ODE-Based Population PK/PD and Systems Pharmacology Models in R with mrgsolve (abstract)
W-024 Wan Sun  Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Neutropenia in Patients With Advanced Cancer Treated With Palbociclib (abstract)
W-025 Timothy H Waterhouse Impact of Model Uncertainty on Phase 2 Diabetes Trial Design  (abstract)
W-026 Chih-Wei Lin Population Pharmacokinetics of a Pangenetic NS5A inhibitor, ABT-530, in HCV infected Patients with and without Cirrhosis (abstract)
W-027 Sébastien Bihorel  Toward Progressive Reporting of Modeling and Simulation Results – Part 1: Analysis of KIWI™ Metadata (abstract)
W-028 Eudy, RJ  Linking a Mechanistic Model of Bone Mineral Density to a Time-to-Event Model to Evaluate Effects of Various Therapies on Fracture Risk in Postmenopausal Women with Osteoporosis (abstract)
W-029 Jason Healy  Development of a Population Pharmacokinetic Model for Vancomycin on an Extracorporeal Membrane Oxygenation (ECMO) Therapy Patient Population (abstract)
W-030 Shuhua Hu  Comparison of Laplacian, Quasi-Random Parametric Expectation Maximization (QRPEM) and Non-parametric Methods for Population Analysis of Complex Dynamic System with Non-static BQL Data (abstract)
W-031 V.Goti  Comparison of Model Based and Model Independent Approaches for Handling Data Below the Limit of Quantitation (abstract)
W-032 Pei Hu Population PK/PD/Survival Modeling Analysis of Icotinib in Chinese Non-Small Cell Lung Cancer Subjects (abstract)
W-033 Devin Pastoor  Translating Older R Data Manipulation Workflows to the Modern Equivalents (abstract)
W-034 Liang Zhao Assessment of Exposure-Response (E-R) and Case-Control (C-C) Analyses in Oncology using Simulation Based Approach (abstract)
W-035 Amita Joshi  Survey of Methodologies for Exposure-Response Analysis of Oncology Drugs Approved in FDA from 2010 to 2015 (abstract)
W-036 Nageshwar R Budha Analysis of Exposure-Response Relationships for Cobimetinib in Combination with Vemurafenib (abstract)
W-037 Martin Boucher Model Based Network Meta-Analysis for Pharmacometrics and Drug-Development: A 3 year Research Collaboration between Pfizer and the University of Bristol (abstract)
W-038 Sebastian Ueckert Modeling the Neuropsychiatric Inventory (NPI) – Strengths and Weaknesses of a Multidimensional Item Response Theory Approach (abstract)
W-039 Manash S. Chatterjee  Model-Based Analysis of the Relationship between Pembrolizumab Exposure and Response in Melanoma  (abstract)
W-040 Mirjam N. Trame Development of a Non-Human Primate PK/PD Model of a Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus (abstract)
W-041 Thuy Vu Optimal Design for Pediatric Study of a Monoclonal Antibody Exhibiting Nonlinear PK (abstract)
W-042 Jin Yan Jin Clinical Trial Simulations to Assess the Probability of Revealing Biomarker Dose-Response in Ph1 Trials (abstract)
W-043 Hartmut Derendorf  Investigating Robustness of Proposed Models to Describe the Novel Mechanism of Atypical Nonlinear Plasma Protein Binding Behavior of Tigecycline (abstract)
W-044 Matts Kågedal  Binning of Exposures in Survival Analysis for Oncology - A Simulation Study (abstract)
W-045 Dan Polhamus  A M&S Framework for Exposure-Response Analysis in Oncology: Comparison and Considerations of Multiple Methodologies (abstract)
W-046 Mathangi Gopalakrishnan Leveraging Biomarkers, Clinical Endpoints, and Exposure-Response Modeling and Simulation to Optimize Phase 3 Dose Selection (abstract)
W-047 Catherine MT Sherwin  Pharmacokinetic Modeling of Plasma and Salivary Caffeine Circulation in Infants Receiving Extended Caffeine Therapy for Intermittent Hypoxia Treatment (abstract)
W-048 Julie Desrochers  To antidote or not? Population Pharmacokinetic Modeling and Bayesian Forecasting as a Tool to Predict the Need for Antidote in Acute Acetaminophen Overdose  (abstract)
W-049 Julie Passarell  Systemization of Logistic Regression Analysis for Pharmacometric Applications (abstract)
W-050 Chetan Rathi  Pharmacokinetic-Pharmacodynamic Analysis of Spectinamide Antibiotic Lee1599 in Mycobacterium tuberculosis Infected Mice (abstract)
W-051 Jeannine Fisher  Effect of Trial Design on Exposure-Response (E-R) Analyses in Rare Diseases: A Simulation Case Study in Duchenne Muscular Dystrophy (DMD) with the 6-Minute-Walk-Test-Distance (6MWTD) Endpoint (abstract)
W-052 Josiah T. Ryman  Modeling the Impact of Antidrug Antibody Formation on the Pharmacokinetics of a Fully Human Monoclonal Antibody in a Preclinical Rodent Model (abstract)
W-053 Jian Xu  Development of a Mega Population Pharmacokinetic (PK) Model of an Antibody-Drug Conjugate (ADC) Platform (abstract)
W-054 Bhargava Kandala A Dynamic Model-Based Analysis of a Multi-Level Glycemic Clamp Study of Regular Human Insulin in T1DM Subjects (abstract)
W-055 John Zhu  Development of a Plasma/Dermis Population Pharmacokinetic Model for GSK1940029 (abstract)
W-056 Ludivine Fronton  Getting Clear on Non-Specific Tissue Clearance of mAbs: Insights from PBPK Modeling (abstract)
W-057  Jürgen Bulitta   Novel Mechanism-based Population Pharmacokinetic/Pharmacodynamic Model of Blood Pressure and the Antihypertensive Activity of Fimasartan (abstract)
W-058 Kenneth Luu  Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Modeling and Covariate Analysis for ISIS GCGRRx (449884),  a Second Generation Antisense Oligonucleotide Glucagon Receptor (GCGR) Inhibitor for the Treatment of Type 2 Diabetes Mellitus (abstract)
W-059 John Harrold  Cell-Level Model of Pharmacodynamics-Mediated Drug Disposition: Application to Filgrastim (Neupogen) (abstract)
W-060 Francois Gaudreault  Assessment of CYP3A-Mediated Drug-Drug-Interaction Potential for PF-X in Healthy Subjects: 
W-061 Weirong Wang   Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model for a Monoclonal Antibody (mAb) against Interleukin-6 in Mice with Collagen-Induced Arthritis (CIA) (abstract)
W-062 Ferdous Gheyas  Pharmacokinetic and Pharmacokinetic / Pharmacodynamic Modeling to Inform Optimal Dose of Vorapaxar  (abstract)
W-063 Loveleena Bansal  Development of a Quantitative Systems Pharmacology (QSP) Model of Psoriasis: Overview and Challenges  (abstract)
W-064 Phyllis Chan  Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects
W-065 Wei Gao Viral Dynamics Modeling of MK-3682 Monotherapy in HCV-infected Patients   (abstract)
W-066 Beesan Tan  Translational PK-PD-Viral Dynamics (VD) Modeling: An Application in Respiratory Syncytial Virus (RSV) Program (abstract)
W-067 Scott Marshall  Application of Model Informed Drug Discovery and Development (MID3) to Gout (abstract)
W-068 D. Zhang  Nonlinear Pharmacokinetics of Letermovir in Phase 1 Suggest a Role of Induction   (abstract)
W-069 Wangda Zhou  Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Children  (abstract)
W-070 Seong-heon Lee Population Pharmacokinetic and Pharmacodynamic Modeling of Ramosetron for the Prophylaxis of Postoperative Nausea and Vomiting (abstract)
W-071 John C. Lukas  Use of Pharmacokinetic and Pharmacodynamic Knowledge of Bilastine for the Optimal Design of the First Pediatric Trial (abstract)